	Dec 14, 2005	Protox files IND for the treatment of prostate cancer
	Dec 12, 2005	Protox files foundation patent for PORxin™ technology
	Dec 6, 2005	Protox Therapeutics Named to 2005 TSX Venture 50
	Nov 29, 2005	Protox releases 3rd Quarter, 2005 financial statements
	Nov 24, 2005	Protox appoints Dr. James Miller to its Board of Directors
	Nov 17, 2005	Protox Completes Oversubscribed $5.8 Million Equity Financing
	Nov 7, 2005	Protox Completes Oversubscribed $4.5 Million Equity Financing
	Oct 27, 2005	Protox Announces $4.0 Million Equity Financing
	Oct 20, 2005	Protox Receives IRB Approval to Conduct Clinical Testing of PRX302 at a Leading U.S. Hospitals
	Sep 21, 2005	Protox Reports Completion of Pre-Clinical Studies for Lead Drug to Support Phase 1 Human Clinical Trials
	Aug 26, 2005	Protox releases 2nd Quarter, 2005 financial statements
	Aug 9, 2005	Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study
	July 13, 2005	Protox appoints Vice President, Business Development
	June 29, 2005	Protox strengthens senior management team
	June 16, 2005	Protox files patent for treatment of Benign Prostatic Hyperplasia
	June 7, 2005	Protox receives funding from NRC to develop lung cancer drug
	May 30, 2005	Protox releases 1st Quarter, 2005 financial statements
	Apr 26, 2005	Protox releases 2004 financial statements
	Apr 20, 2005	Protox reports efficacy data of prostate cancer drug in animals
	Apr 18, 2005	Protox Announces Change to Senior Management
	Apr 14, 2005	Protox Efficacy Data to be Presented at Leading Cancer Research Conference
	Apr 5, 2005	Protox exercises Lung Cancer Licence option with the NRC Institute for Biological Sciences and with the University of Victoria
	Mar 2, 2005	Protox appoints Fahar Merchant as Vice President, Corporate Development
	Feb 23, 2005	Protox Chief Scientific Officer wins Entrepreneurship Award
	Jan 11, 2005	Protox Achieves milestone towards an IND Filing

What's New

September 3, 2008
Protox Completes Enrollment Of Phase 2 BPH Trial

August 11, 2008
Protox Reports 2008 Second Quarter Results

June 17, 2008
Protox Granted Orphan Status In Europe For Brain Cancer Treatment

May 23, 2008
Protox Completes $4.8 Million Private Placement

Events

BioFinance
Toronto Marriott Eaton Centre Hotel (Trinity IV room) - Toronto, ON

When: May 7, 2008 10:30a.m. EDT

Presenter: Dr. Fahar Merchant, President & CEO

Stock Quote

	LAST TRADE:	$0.60
	TRADE TIME:	3:24PM EST
	CHANGE:	$0.00 (0.00%)
	PREV CLOSE:	$0.60
	OPEN:	$0.64
	BID:	$0.60
	ASK:	$0.65